This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Advanced Accelerator Applications SA
Drug Names(s): PSMA-SR6
PSMA-SR6 is a second-generation selective prostate cancer Prostate-Specific Membrane Antigen (PSMA) receptor ligand. It's structure is selective for PSMA expressed on prostate cancer tumor cells.
Advanced Accelerator Applications plans to radiolabel PSMA-SR6 to develop a 177Lu-PSMA-SR6 to treat and monitor prostate cancer and a 68Ga-PSMA-SR6, which will help to diagnose and stage disease.
Advanced Accelerator Applications and Johns Hopkins University
In January 2016, Advanced Accelerator Applications announced an exclusive license agreement with Johns Hopkins University to develop and market PSMA-SR6, a receptor ligand of Prostate-Specific Membrane Antigen (PSMA) for clinical therapeutic and diagnostic purposes. The terms of the agreement include payment to Johns Hopkins of an upfront licensing fee, as well as certain milestone and royalty payments.
Additional information available to subscribers only: